Resumen de las cotizaciones máximas, mínimas y variaciones del Evaxion
Precios históricos de las acciones
Precio actual de la acción	US$3.09
Máximo en las últimas 52 semanas	US$12.15
Mínimo de 52 semanas	US$2.26
Beta	0.23
Cambio en 1 mes	-22.75%
Variación en 3 meses	-16.94%
Cambio de 1 año	26.12%
Variación en 3 años	-95.25%
Variación en 5 años	-99.15%
Variación desde la OPV	-99.38%

Noticias y actualizaciones recientes

Actualización de narrativa • Jun 26

EVAX: AI-Immunology Pipeline Progress Will Drive Future Upside Potential

Analysts have lowered their price target on Evaxion from $14.19 to $11.25, reflecting the application of a slightly higher discount rate and more moderate assumptions for revenue growth and profit margin, which in turn leads to a higher expected future P/E. What’s in the News for Evaxion Evaxion reported new preclinical data for EVX-04, an off-the-shelf therapeutic vaccine candidate for acute myeloid leukemia, with poster data set for presentation at the European Hematology Association 2026 Congress in Stockholm, Sweden.

Recent updates

Actualización de narrativa • Jun 26

EVAX: AI-Immunology Pipeline Progress Will Drive Future Upside Potential

Nueva narrativa • Mar 11

AI Immunology Platform Will Face Partnership Risks Yet Eventually Reward Long-Term Patience

Catalysts About Evaxion Evaxion is a biotech company that applies its AI-Immunology platform to discover and design vaccines and immunotherapies in oncology, infectious disease and potentially autoimmune conditions. What are the underlying business or industry changes driving this perspective?

Seeking Alpha • May 26

Evaxion: Progress Unrecognized By Market And A Catalyst-Full 2025

Summary Evaxion has demonstrated impressive in-house capabilities for discovering and developing vaccine candidates for both infectious diseases and oncology indications. Partnership with MSD, albeit heavily backloaded, provides considerable validation of Evaxion's value. A potential option exercise by MSD expected later this year would bring in up to $10M. EVAX guides a cash runway into mid-2026, which could be extended into 2027 if MSD exercises options for both partnered candidates (not accounting for potential further business developments). EVAX aims for at least 2 new deals in 2025 and is in the meantime further developing its AI platform to stay ahead of competition. Read the full article on Seeking Alpha

Seeking Alpha • Mar 31

Evaxion: An Intriguing AI Vaccine Company With Big Pharma Collaboration

Summary Evaxion's sophisticated AI Immunology platform aims to outperform competitors in vaccine development, in both oncology and infectious diseases indications. The company has already established three collaborations, including a partnership with MSD, and has raised enough funding to last through 2024. Evaxion's AI models, including EDEN, RAVEN, PIONEER, ObsERV, and AI-DEEP, show promise in identifying protective antigens, designing effective and safe personalized cancer vaccines and predicting which patients will respond. Big pharma interest, pending catalysts in 2024, impressive proof-of-concept preclinical and clinical data are compelling enough for me for a small speculative position. However, the risk of considerably more dilutive funding as well as the very early stage of the pipeline make me give a "Hold" recommendation. Read the full article on Seeking Alpha

Seeking Alpha • Oct 05

Evaxion Biotech names Per Norlén as CEO

Evaxion Biotech (EVAX) said Wednesday Per Norlén joined the firm as CEO on Monday. Norlén is a physician and associate professor with over 20 years in the biotech sector, of which the last decade has been in executive leadership roles.

Seeking Alpha • Sep 21

Evaxion stock rises 11% as enrollment begins in trial of immunotherapy EVX-01 for skin cancer

Evaxion Biotech (EVAX) said it enrolled its first patient in a global phase 2b trial of its immunotherapy EVX-01 to treat melanoma, a type of skin cancer. The trial is being conducted at sites in the the U.S., Europe, and Australia in collaboration with Merck (NYSE:MRK) which is supplying the trial with its blockbuster drug Keytruda, the Danish company said in a Sept. 21 press release. Patients will receive standard of care treatment along with Keytruda in combination with EVX-01. Evaxion added that it is responsible for conducting the trial. The company expects interim topline data in H2 2023. EVAX +11.27% to $2.27 premarket Sept. 21

Seeking Alpha • Aug 10

Evaxion Biotech ADS GAAP EPS of -$0.20 beats by $0.10

Evaxion Biotech ADS press release (EVAX): Q2 GAAP EPS of -$0.20 beats by $0.10. As of June 30, 2022, cash and cash equivalents were $25.3M as compared to $32.2M as of December 31, 2021. We expect our existing cash and cash equivalents, including use of financing facilities, will be sufficient to fund our operating expenses and capital expenditure requirements through at least the next 12 months.

Seeking Alpha • Aug 02

Evaxion Biotech announces new CEO as Lars Wegner resigns

Evaxion Biotech (EVAX) announced Tuesday the resignation of chief executive officer Lars Staal Wegner. The clinical-stage biotech company said Per Norlén, M.D., PhD., has been appointed to succeed Wegner. Norlén is a physician and board certified specialist in clinical pharmacology with over 20 years of working in clinical drug development. Most recently, Dr. Norlén was Chief Executive Officer of Targinta AB and Chief Medical Officer of Xintela AB, Targinta is a wholly owned subsidiary of Xintela, a publicly listed company on the Nasdaq First North Growth Market Stockholm, Sweden. Earlier: Evaxion Biotech to advance DNA vaccine into non-small cell lung cancer indication

Rentabilidad de los accionistas

	EVAX	US Biotechs	Mercado US
7D	-9.6%	7.5%	-2.5%
1Y	26.1%	40.9%	19.0%

Rentabilidad vs. Industria: Los resultados de EVAX fueron inferiores a los de la industria US Biotechs, que obtuvo un rendimiento del 40.9% el año pasado.

Rentabilidad vs. Mercado: EVAX superó al mercado US, que obtuvo un rendimiento del 19% el año pasado.

Volatilidad de los precios

Is EVAX's price volatile compared to industry and market?
EVAX volatility
EVAX Average Weekly Movement	9.5%
Biotechs Industry Average Movement	10.5%
Market Average Movement	7.3%
10% most volatile stocks in US Market	16.8%
10% least volatile stocks in US Market	3.1%

Precio estable de las acciones: EVAX no ha tenido una volatilidad de precios significativa en los últimos 3 meses en comparación con el mercado US.

Volatilidad a lo largo del tiempo: La volatilidad semanal de EVAX ha disminuido de 16% a 9% en el último año.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
2008	46	Helen Tayton-Martin	evaxion.ai

Evaxion A/S, empresa biotecnológica en fase clínica, desarrolla vacunas inmunológicas impulsadas por inteligencia artificial. La empresa desarrolla EVX-01, que está en fase 2 de ensayo clínico multicéntrico mundial para el tratamiento del melanoma avanzado; EVX-03, vacuna contra el cáncer basada en ADN para el tratamiento de tumores sólidos; y EVX-04, candidata a vacuna terapéutica contra el cáncer, que está en fase 1 de ensayo para la leucemia mieloide aguda. Sus programas también incluyen vacunas en fase preclínica, como EVX-B1, una vacuna profiláctica multicomponente contra las infecciones de piel y tejidos blandos causadas por la bacteria S. aureus; EVX-B2, una vacuna profiláctica multicomponente contra la bacteria de la gonorrea; EVX-B3, un patógeno bacteriano asociado a infecciones repetidas; y EVX-V1, una vacuna profiláctica multicomponente contra el citomegalovirus.

Resumen de fundamentos de Evaxion A/S

¿Cómo se comparan los beneficios e ingresos de Evaxion con su capitalización de mercado?
Estadísticas fundamentales de EVAX
Capitalización bursátil	US$25.77m
Beneficios(TTM)	-US$9.76m
Ingresos (TTM)	US$7.53m

3.4x

Ratio precio-ventas (PS)

-2.6x

Ratio precio-beneficio (PE)

¿Está EVAX sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de EVAX
Ingresos	US$7.53m
Coste de los ingresos	US$0
Beneficio bruto	US$7.53m
Otros gastos	US$17.28m
Beneficios	-US$9.76m

Últimos beneficios comunicados

Mar 31, 2026

Próxima fecha de beneficios

Aug 20, 2026

Beneficios por acción (BPA)	-1.17
Margen bruto	100.00%
Margen de beneficio neto	-129.60%
Ratio deuda/patrimonio	0%

¿Cómo se ha desempeñado EVAX a largo plazo?

Ver rendimiento histórico y comparativa

Análisis de la empresa y estado de los datos financieros

Datos	Última actualización (huso horario UTC)
Análisis de la empresa	2026/06/29 17:38
Precio de las acciones al final del día	2026/06/26 00:00
Beneficios	2026/03/31
Ingresos anuales	2025/12/31

Fuentes de datos

Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.

Paquete	Datos	Marco temporal	Ejemplo Fuente EE.UU. ^*
Finanzas de la empresa	10 años	Cuenta de resultados Estado de tesorería Balance	Formulario SEC 10-K Formulario SEC 10-Q
Estimaciones del consenso de analistas	+3 años	Previsiones financieras Objetivos de precios de los analistas	Informes de análisis Blue Matrix
Precios de mercado	30 años	Precios de las acciones Dividendos, escisiones y acciones	Datos de mercado ICE Formulario S-1 de la SEC
Propiedad	10 años	Accionistas principales Información privilegiada	Formulario SEC 4 Formulario SEC 13D
Gestión	10 años	Equipo directivo Consejo de Administración	Formulario SEC 10-K Formulario SEC DEF 14A
Principales avances	10 años	Anuncios de empresas	Formulario SEC 8-K

^* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.

A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.

Modelo de análisis y copo de nieve

Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también contamos con guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.

Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.

Métricas industriales y sectoriales

Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.

Fuentes analistas

Evaxion A/S está cubierta por 6 analistas. 4 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.

Analista	Institución
Swayampakula Ramakanth	H.C. Wainwright & Co.
Soumit Roy	JonesTrading Institutional Services, LLC
Debanjana Chatterjee	JonesTrading Institutional Services, LLC

Evaxion (EVAX) Resumen de Acciones

Recompensas

Análisis de riesgos

Analyst Price Targets

AI Immunology Platform Will Face Partnership Risks Yet Eventually Reward Long-Term Patience

AI Immunology Partnerships And Pipeline Progress Will Drive Long Term Value

AI-Driven Vaccine Partnerships And Dark Genome Targets Will Shape Long-Term Opportunity

Top Community Narratives

The "AI-Immunology" Asymmetric Opportunity – Validated by Merck (MSD)

Top Community Narratives

The "AI-Immunology" Asymmetric Opportunity – Validated by Merck (MSD)

Top Analyst Narratives

AI Immunology Platform Will Face Partnership Risks Yet Eventually Reward Long-Term Patience

AI Immunology Partnerships And Pipeline Progress Will Drive Long Term Value

AI-Driven Vaccine Partnerships And Dark Genome Targets Will Shape Long-Term Opportunity

Competidores de Evaxion A/S

Harvard Apparatus Regenerative Technology

Cyclerion Therapeutics

Apollomics

Pluri

Historial de precios y rendimiento

Noticias y actualizaciones recientes

EVAX: AI-Immunology Pipeline Progress Will Drive Future Upside Potential

Evaxion A/S Presents New Preclinical Data For EVX-04, An Off-The-Shelf Therapeutic Vaccine For Acute Myeloid Leukemia

Evaxion A/S Promotes Birgitte Rønø as Chief Scientific and Chief Operating Officer

Evaxion A/S Demonstrates Scalability of Ai-Immunology Platform in Glioblastoma

Evaxion A/S Elects Jens Bitsch Nørhave to the Board of Directors

Evaxion A/S Announces Last Patient Visit in One-Year Extension of Phase 2 Trial with Personalized Cancer Vaccine Evx-01

Recent updates

EVAX: AI-Immunology Pipeline Progress Will Drive Future Upside Potential

Evaxion A/S Presents New Preclinical Data For EVX-04, An Off-The-Shelf Therapeutic Vaccine For Acute Myeloid Leukemia

Evaxion A/S Promotes Birgitte Rønø as Chief Scientific and Chief Operating Officer

Evaxion A/S Demonstrates Scalability of Ai-Immunology Platform in Glioblastoma

Evaxion A/S Elects Jens Bitsch Nørhave to the Board of Directors

Evaxion A/S Announces Last Patient Visit in One-Year Extension of Phase 2 Trial with Personalized Cancer Vaccine Evx-01

Evaxion A S Presents Novel AI Based Polio Vaccine Design Concepts and Evx V1 Cmv Vaccine Program

Evaxion A/S, Annual General Meeting, Apr 16, 2026

AI Immunology Platform Will Face Partnership Risks Yet Eventually Reward Long-Term Patience

Evaxion A/S Expands AI-Immunology Platform Into Autoimmune Diseases

Evaxion A/S to Report Q3, 2026 Results on Nov 19, 2026

Evaxion A/S to Report Q3, 2025 Results on Nov 06, 2025

Evaxion A/S Announces Dr Helen Tayton-Martin Stepping Down from the Board

Evaxion A/S Announces New Two-Year Unprecedented Clinical Efficacy Data of Its Personalized Cancer Vaccine EVX-01 in Patients with Advanced Melanoma

Evaxion A/S to Present New Biomarker Data for AI- Designed Personalized Cancer Vaccine EVX-01 At the SITC 2025 Annual Meeting

Evaxion A/S to Report Q2, 2025 Results on Aug 14, 2025

Evaxion A/S to Present Two-Year Clinical Efficacy Data from Phase 2 Trial with AI- Designed Personalized Cancer Vaccine EVX-01 at the ESMO Congress 2025

Evaxion A/S Announces CEO Changes

Evaxion Expands R&D Pipeline with New Vaccine Program Targeting Group A Streptococcus

Evaxion: Progress Unrecognized By Market And A Catalyst-Full 2025

Evaxion A/S to Report Q1, 2025 Results on May 27, 2025

Evaxion Doses First Patient in Extension of Phase 2 Trial Exploring the Full Potential of Ai- Designed Personalized Cancer Vaccine Evx-01

Evaxion Biotech A/S Presents striking EVX-01 Data at the AACR Annual Meeting

Evaxion Biotech A/S, Annual General Meeting, Apr 30, 2025

Evaxion Biotech A/S has completed a Follow-on Equity Offering in the amount of $4.48 million.

Evaxion Biotech A/S Extends Phase 2 Trial with AI-Immunology™?

Nasdaq Confirms Evaxion Is Fully Compliant, Withdraws Delisting Determination

Evaxion Completes Dosing in Phase 2 Trial with Personalized Cancer Vaccine EVX-01

Evaxion Biotech A/S Establishes New AI-Derived Precision Cancer Vaccine Concept

Evaxion Biotech A/S has filed a Follow-on Equity Offering in the amount of $12.5 million.

Evaxion Announces Positive Preclinical Data for Cytomegalovirus (CMV) Vaccine Program EVX-V1

Evaxion Update on Nasdaq Notification Regarding Minimum Stockholders’ Equity Requirement

Evaxion Biotech A/S to Report Q3, 2024 Results on Oct 31, 2024

Evaxion Biotech A/S Announces Strong Validation of Ai-Immunology Platform in Multiple Clinical Trials

Evaxion Biotech A/S Continues to Grows Clinical Evidence for the Steady Improvement of Its Ai-Immunology Platform

Evaxion Biotech A/S Reports Convincing One-Year Data from Phase 2 Trial on AI-Designed Personalized Cancer Vaccine EVX-01

Evaxion Biotech A/S Reports 69% Overall Response Rate in its Phase 2 Trial on Lead Cancer Vaccine Candidate EVX-01

Consensus revenue estimates increase by 331%

Evaxion Biotech A/S to Report Q2, 2024 Results on Aug 14, 2024

Evaxion Biotech A/S Announces Publication of Data from Its Phase 1 Dose Escalation Study of Its Lead Personalized Cancer Vaccine, EVX-01

Consensus revenue estimates decrease by 97%, EPS upgraded

Consensus revenue estimates decrease by 24%, EPS upgraded

New major risk - Financial position

Evaxion Biotech A/S to Present New Positive Data from Ongoing Phase 2 Study on Lead Vaccine Candidate EVX-01 at the American Society of Clinical Oncology Annual Meeting 2024

Evaxion Announces Phase 2 Clinical Trial Update

Evaxion and Undisclosed Collaborator Announce Encouraging Results for Evx-B1 Vaccine Antigens Against Staphylococcus Aureus Infection

Consensus revenue estimates increase by 33%, EPS downgraded

Evaxion: An Intriguing AI Vaccine Company With Big Pharma Collaboration

Evaxion Biotech A/S, Annual General Meeting, Apr 16, 2024

Forecast to breakeven in 2025

Evaxion Biotech A/S has completed a Follow-on Equity Offering in the amount of $15 million.